Gilead Sciences | GILD - Operating Expenses

Stock Price
130.40
Daily Change
-3.24 -2.42%
Monthly
-5.68%
Yearly
26.39%
Q2 Forecast
127.61

Gilead Sciences reported $4.96B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025